RIDGEWOOD, N.J., July 2, 2026
Oliva Therapeutics, LLC announced the commercial launch of Amerithroid™ (Thyroid Tablets, USP), a naturally derived desiccated thyroid extract (DTE) therapy designed for the treatment of hypothyroidism. The new product provides both levothyroxine (T4) and liothyronine (T3) in a single formulation and is sourced and manufactured entirely in the United States by Jerome Stevens Pharmaceuticals (JSP). The launch expands Oliva Therapeutics’ endocrine portfolio and offers healthcare providers and patients an additional thyroid hormone replacement option supported by domestic manufacturing. Amerithroid builds on JSP’s long-standing expertise in thyroid therapies, including the development of Unithroid®, the first FDA-approved levothyroxine sodium tablet, reinforcing the company’s commitment to quality, supply reliability, and consistent manufacturing standards.
U.S.-Made Thyroid Therapy Expands Treatment Options
Amerithroid delivers both T3 and T4 thyroid hormones, providing a naturally derived alternative for patients requiring thyroid hormone replacement therapy. According to Oliva Therapeutics, the product is manufactured exclusively in the United States using domestic sourcing, addressing increasing interest in Made-in-America pharmaceutical manufacturing and dependable product availability. Chief Executive Officer Daniel Akeson said the launch reflects years of development and the company’s commitment to providing high-quality thyroid medications backed by American manufacturing expertise. The company emphasized that the introduction of Amerithroid strengthens its long-term strategy of delivering trusted endocrine therapies while supporting physicians with additional treatment choices for patients living with hypothyroidism.
Growing Endocrine Portfolio Supports Patient Care
The launch of Amerithroid follows the successful relaunch of Thyquidity® (Levothyroxine Sodium Oral Solution), an FDA-approved liquid thyroid replacement therapy developed for patients who experience difficulty swallowing tablets, including pediatric populations. Thyquidity is indicated for the treatment of primary, secondary, and tertiary congenital or acquired hypothyroidism, broadening Oliva’s endocrine product offerings. Chief Operating Officer Michael Turnamian stated that the company’s commercial team is actively engaging endocrinologists and healthcare providers to discuss treatment options that best meet individual patient needs. By offering both tablet and liquid formulations, Oliva aims to improve treatment flexibility while expanding physician access to specialized thyroid therapies.
Advertisement
Strategic Growth Focuses on U.S. Manufacturing and Thyroid Care
The commercial introduction of Amerithroid represents another milestone in Oliva Therapeutics’ endocrine-focused growth strategy. Through its partnership with Jerome Stevens Pharmaceuticals, the company is leveraging decades of pharmaceutical manufacturing experience to strengthen supply reliability and product consistency in the thyroid care market. As demand continues to grow for high-quality thyroid hormone replacement therapies, Oliva is positioning its expanding portfolio to address the needs of patients with hypothyroidism while reinforcing the value of U.S.-based pharmaceutical production. The launch also underscores the company’s broader commitment to delivering innovative, patient-focused endocrine treatments supported by established manufacturing expertise and long-term investment in thyroid disease management.
Source: Oliva Therapeutics press release
